<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758043</url>
  </required_header>
  <id_info>
    <org_study_id>VX08-950-111</org_study_id>
    <secondary_id>EudraCT 2008-003836-39</secondary_id>
    <nct_id>NCT00758043</nct_id>
  </id_info>
  <brief_title>A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response</brief_title>
  <official_title>A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to learn more about the safety and effect of telaprevir in
      combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with
      hepatitis C who have never been treated for their hepatitis C virus (HCV). The study is
      designed to look at the relative benefits of 24 or 48 weeks of total treatment in people who
      respond quickly to a telaprevir-based treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)</measure>
    <time_frame>24 weeks after the last planned dose of study treatment</time_frame>
    <description>SVR24planned was used to measure the primary outcome. SVR24 planned is defined as undetectable HCV RNA levels at the end of treatment (EOT) visit and at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA levels in between those visits. All plasma HCV RNA levels were assessed using the Roche TaqMan HCV RNA assay (Version 2.0, lower limit of quantification [LLOQ] of 25 IU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Have Undetectable HCV RNA at Week 72</measure>
    <time_frame>72 weeks after the last planned dose of study treatment</time_frame>
    <description>SVR at Week 72 is defined as achieved SVR24planned and undetectable HCV RNA at Week 72 without any confirmed detectable HCV RNA levels in between those visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Extended rapid viral response is defined undetectable HCV RNA levels at Week 4 and Week 12 (on treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment</measure>
    <time_frame>12 weeks after last dose of study treatment</time_frame>
    <description>SVR12 is defined as undetectable HCV RNA levels 12 weeks after the last planned dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Randomized Subjects Who Relapse, Defined as Those Who Complete Treatment, Have Undetectable HCV RNA at End of Treatment (EOT; Week 24 or Week 48 Respectively), and Become HCV RNA Detectable During Antiviral Follow-up</measure>
    <time_frame>Week 24 or Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Enrolled Subjects Who Relapse, Defined as Those Who Have Undetectable HCV RNA at the EOT, and Become HCV RNA Detectable During Antiviral Follow-up</measure>
    <time_frame>Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively).</measure>
    <time_frame>Week 24 or Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events, Physical Examination Findings, and Clinical Laboratory, Vital Sign, and Electrocardiogram (ECG) Assessments</measure>
    <time_frame>Week 72</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>T12PR24 (eRVR+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T12PR48 (eRVR+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T12PR48 (eRVR-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telaprevir</intervention_name>
    <description>750 mg every 8 hours (q8h) for 12 weeks</description>
    <arm_group_label>T12PR24 (eRVR+)</arm_group_label>
    <arm_group_label>T12PR48 (eRVR+)</arm_group_label>
    <arm_group_label>T12PR48 (eRVR-)</arm_group_label>
    <arm_group_label>Other</arm_group_label>
    <other_name>VX-950</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>1000 - 1200 mg/day based on body weight for either 24 or 48 weeks</description>
    <arm_group_label>T12PR24 (eRVR+)</arm_group_label>
    <arm_group_label>T12PR48 (eRVR+)</arm_group_label>
    <arm_group_label>T12PR48 (eRVR-)</arm_group_label>
    <arm_group_label>Other</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2a</intervention_name>
    <description>180 mcg/week for either 24 or 48 weeks</description>
    <arm_group_label>T12PR24 (eRVR+)</arm_group_label>
    <arm_group_label>T12PR48 (eRVR+)</arm_group_label>
    <arm_group_label>T12PR48 (eRVR-)</arm_group_label>
    <arm_group_label>Other</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has not received any previous treatment with any approved or investigational drug or
             drug regimen for the treatment of hepatitis C

          -  Male and female subjects, 18 to 70 years of age, inclusive

          -  Genotype 1, chronic hepatitis C with detectable HCV RNA.

          -  Screening laboratory values, tests, and physical exam within acceptable ranges

          -  Able and willing to follow contraception requirements

          -  Able to read and understand, and willing to sign the informed consent form and abide
             by the study restrictions.

        Exclusion Criteria:

          -  Subject has any contraindications to Pegasys® or Copegus® therapy

          -  Evidence of hepatic decompensation in cirrhotic subjects

          -  History of organ transplant

          -  History of, or any current medical condition which could impact the safety of the
             subject in participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Adler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Hospital Bruxelles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hendrik Reesink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center of the University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Sherman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20783</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantic City</city>
        <state>New Jersey</state>
        <zip>08401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bayside</city>
        <state>New York</state>
        <zip>11358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <zip>B1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <zip>B1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège 1</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <results_first_submitted>June 22, 2011</results_first_submitted>
  <results_first_submitted_qc>June 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2011</results_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T12PR24 (eRVR+)</title>
          <description>Telaprevir + peginterferon-alfa-2a (Peg-IFN-alfa-2a) + ribavirin (RBV) for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
        </group>
        <group group_id="P2">
          <title>T12PR48 (eRVR+)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
        </group>
        <group group_id="P3">
          <title>T12PR48 (eRVR-)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response (eRVR-) and were assigned to this group</description>
        </group>
        <group group_id="P4">
          <title>Other</title>
          <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20 were not randomized or assigned to a treatment regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Further Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliant With study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T12PR24 (eRVR+)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
        </group>
        <group group_id="B2">
          <title>T12PR48 (eRVR+)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
        </group>
        <group group_id="B3">
          <title>T12PR48 (eRVR-)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response (eRVR-) and were assigned to this group</description>
        </group>
        <group group_id="B4">
          <title>Other</title>
          <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20 were not randomized or assigned to a treatment regimen.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="160"/>
            <count group_id="B3" value="118"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="540"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="8.9"/>
                    <measurement group_id="B2" value="48.3" spread="9.9"/>
                    <measurement group_id="B3" value="49.5" spread="8.7"/>
                    <measurement group_id="B4" value="51.6" spread="8.4"/>
                    <measurement group_id="B5" value="49.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)</title>
        <description>SVR24planned was used to measure the primary outcome. SVR24 planned is defined as undetectable HCV RNA levels at the end of treatment (EOT) visit and at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA levels in between those visits. All plasma HCV RNA levels were assessed using the Roche TaqMan HCV RNA assay (Version 2.0, lower limit of quantification [LLOQ] of 25 IU/mL).</description>
        <time_frame>24 weeks after the last planned dose of study treatment</time_frame>
        <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>T12PR24 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
          </group>
          <group group_id="O2">
            <title>T12PR48 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
          </group>
          <group group_id="O3">
            <title>T12PR48 (eRVR-)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response (eRVR-) and were assigned to this group</description>
          </group>
          <group group_id="O4">
            <title>Other</title>
            <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20 were not randomized or assigned to a treatment regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)</title>
          <description>SVR24planned was used to measure the primary outcome. SVR24 planned is defined as undetectable HCV RNA levels at the end of treatment (EOT) visit and at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA levels in between those visits. All plasma HCV RNA levels were assessed using the Roche TaqMan HCV RNA assay (Version 2.0, lower limit of quantification [LLOQ] of 25 IU/mL).</description>
          <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR24 (Statistical Analysis 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24 (Statistical Analysis 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary efficacy analysis was based on CI estimates (using the normal approximation, confidence limits were constructed for the difference in proportions) to rule out the inferiority of the T12/PR24/eRVR+ treatment regimen relative to the T12/PR48/eRVR+ treatment regimen. SVR24 was defined as undetectable HCV RNA at end of treatment through 24 weeks after the last planned dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimated by evaluating the treatment differences in the SVR24planned rates (T12PR24/eRVR+ minus T12PR48/eRVR+) and the 95% CI for these groups (the entire 2 sided CI is to the right of the predefined non-inferiority margin of -10.5%).</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SVR24 was defined as below the limit of quantitation at 24 weeks after the planned end of treatment. For subjects who had missing data at week 24 after the planned end of treatment, the week 12 data or the last follow-up time point after week 12 was carried forward for determining SVR24.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimated by evaluating the treatment differences in the SVR24planned rates (T12PR24/eRVR+ minus T12PR48/eRVR+) and the 95% CI for these groups (the entire 2 sided CI is to the right of the predefined non-inferiority margin of -10.5%).</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Have Undetectable HCV RNA at Week 72</title>
        <description>SVR at Week 72 is defined as achieved SVR24planned and undetectable HCV RNA at Week 72 without any confirmed detectable HCV RNA levels in between those visits.</description>
        <time_frame>72 weeks after the last planned dose of study treatment</time_frame>
        <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>T12PR24 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response and were randomized to this group</description>
          </group>
          <group group_id="O2">
            <title>T12PR48 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response and were randomized to this group</description>
          </group>
          <group group_id="O3">
            <title>T12PR48 (eRVR-)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response and were assigned to this group (not randomized)</description>
          </group>
          <group group_id="O4">
            <title>Other</title>
            <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Have Undetectable HCV RNA at Week 72</title>
          <description>SVR at Week 72 is defined as achieved SVR24planned and undetectable HCV RNA at Week 72 without any confirmed detectable HCV RNA levels in between those visits.</description>
          <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimated by evaluating the treatment differences in the SVR at Week 72 planned rates (T12PR24/eRVR+ minus T12PR48/eRVR+) and the 95% CI for these groups (the entire 2 sided CI is to the right of the predefined non-inferiority margin of 10.5%).</non_inferiority_desc>
            <param_type>Difference in Proportion</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimated by evaluating the treatment differences in the SVR at Week 72 planned rates (T12PR24/eRVR+ minus T12PR48/eRVR+) and the 95% CI for these groups (the entire 2 sided CI is to the right of the predefined non-inferiority margin of 10.5%).</non_inferiority_desc>
            <param_type>Odds Ratio, log</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</title>
        <description>Extended rapid viral response is defined undetectable HCV RNA levels at Week 4 and Week 12 (on treatment).</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>T12PR24 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response and were randomized to this group</description>
          </group>
          <group group_id="O2">
            <title>T12PR48 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response and were randomized to this group</description>
          </group>
          <group group_id="O3">
            <title>T12PR48 (eRVR-)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response and were assigned to this group (not randomized)</description>
          </group>
          <group group_id="O4">
            <title>Other</title>
            <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</title>
          <description>Extended rapid viral response is defined undetectable HCV RNA levels at Week 4 and Week 12 (on treatment).</description>
          <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment</title>
        <description>SVR12 is defined as undetectable HCV RNA levels 12 weeks after the last planned dose of study treatment.</description>
        <time_frame>12 weeks after last dose of study treatment</time_frame>
        <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>T12PR24 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
          </group>
          <group group_id="O2">
            <title>T12PR48 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
          </group>
          <group group_id="O3">
            <title>T12PR48 (eRVR-)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response (eRVR-) and were assigned to this group</description>
          </group>
          <group group_id="O4">
            <title>Other</title>
            <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20 were not randomized or assigned to a treatment regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment</title>
          <description>SVR12 is defined as undetectable HCV RNA levels 12 weeks after the last planned dose of study treatment.</description>
          <population>The population analyzed included all subjects in the Full Analysis (FA) Set. All subjects in the FA Set received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Randomized Subjects Who Relapse, Defined as Those Who Complete Treatment, Have Undetectable HCV RNA at End of Treatment (EOT; Week 24 or Week 48 Respectively), and Become HCV RNA Detectable During Antiviral Follow-up</title>
        <time_frame>Week 24 or Week 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Enrolled Subjects Who Relapse, Defined as Those Who Have Undetectable HCV RNA at the EOT, and Become HCV RNA Detectable During Antiviral Follow-up</title>
        <time_frame>Week 72</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively).</title>
        <time_frame>Week 24 or Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T12PR24 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response and were randomized to this group</description>
          </group>
          <group group_id="O2">
            <title>T12PR48 (eRVR+)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response and were randomized to this group</description>
          </group>
          <group group_id="O3">
            <title>T12PR48 (eRVR-)</title>
            <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response and were assigned to this group (not randomized)</description>
          </group>
          <group group_id="O4">
            <title>Other</title>
            <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively).</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events, Physical Examination Findings, and Clinical Laboratory, Vital Sign, and Electrocardiogram (ECG) Assessments</title>
        <time_frame>Week 72</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>T12PR24 (eRVR+)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 12 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
        </group>
        <group group_id="E2">
          <title>T12PR48 (eRVR+)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group</description>
        </group>
        <group group_id="E3">
          <title>T12PR48 (eRVR-)</title>
          <description>Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by 36 weeks of Peg-IFN-alfa-2a and RBV; subjects did not achieve an extended rapid viral response (eRVR-) and were assigned to this group</description>
        </group>
        <group group_id="E4">
          <title>Other</title>
          <description>Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20 were not randomized or assigned to a treatment regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ANAEMIA HAEMOLYTIC AUTOIMMUNE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMORRHAGIC ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>PAPILLOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>POLYMYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>THROAT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MANIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CRYPTOGENIC ORGANISING PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ANORECTAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ANAL PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INJECTION SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>RASH MACULAR</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Kauffman, MD, PhD</name_or_title>
      <organization>Vertex Pharmaceuticals Incorporated</organization>
      <phone>617-444-6158</phone>
      <email>Robert_Kauffman@vrtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

